文献速递眼整形与眼眶神经眼科

替妥木单抗改善不对称甲状腺眼病

Improvement of asymmetric thyroid eye disease with teprotumumab.
PubMed 文献 · Br J Ophthalmol · 2021-02-12

该研究汇总分析两项随机对照试验中不对称甲状腺眼病患者,评估替妥木单抗对双眼的差异影响。结果显示替妥木单抗在双眼均显著降低突眼度、CAS和复视,且对受累更重眼眶的突眼度和CAS改善更显著,缩小了不对称性,安慰剂组未见此效应。

要点

  • 替妥木单抗治疗不对称甲状腺眼病可显著降低双眼突眼度、CAS和复视。
  • 对受累更重眼眶的突眼度和CAS改善更显著,缩小双眼不对称。
  • 安慰剂组研究眼CAS均值随时间下降,但双眼突眼度和复视无变化。

核心结论

  • 替妥木单抗对临床受累更重的眼眶有差异化影响,可减少不对称性。

研究设计与样本

  • 汇总分析2期试验NCT01868997和3期试验NCT03298867中随机接受替妥木单抗或安慰剂的患者。
  • 筛选不对称甲状腺眼病(突眼计差值≥3 mm)患者,评估双眼从基线至第24周的突眼度、复视和CAS反应。

主要发现

  • 替妥木单抗组84例中10例(12%)、安慰剂组87例中12例(14%)符合纳入标准。
  • 替妥木单抗组双眼突眼度、CAS和复视均显著降低,安慰剂组未见。
  • 替妥木单抗组受累更重眼眶的突眼度和CAS降低显著更大,改善对称性。
  • 安慰剂组研究眼CAS均值随时间下降,但双眼突眼度和复视无变化。

临床怎么用

  • 对不对称甲状腺眼病患者,替妥木单抗可能缩小双眼不对称性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Teprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in patients with asymmetric TED. Herein, we investigate the differential impact of teprotumumab on the orbits of such patients. METHODS: In this pooled analysis of patients who were enrolled in the recent phase 2 (NCT01868997) and phase 3 (NCT03298867) trials, all patients with asymmetric TED (difference in exophthalmometry of ≥3 mm) were screened for eligibility. The primary outcomes of the trials, proptosis, diplopia and Clinical Activity Score (CAS) response, were evaluated in both orbits of patients who had received treatment or placebo, to examine the differential response from baseline to week 24. RESULTS: From a pooled group of 84 patients randomised to receive teprotumumab and 87 randomised to placebo, 10 (12%) and 12 (14%), respectively, met the inclusion criteria. The teprotumumab-treated patients demonstrated significant reductions in proptosis, CAS and diplopia in both orbits of each patient and this was not seen with placebo. The reduction in proptosis and CAS was significantly greater in the worse affected orbit, improving symmetry. In the placebo arm, while the mean CAS in the study eye reduced over time, proptosis and diplopia did not change in either orbit. CONCLUSION: The findings in this study suggest the differential impact of teprotumumab on orbits that are clinically more affected by TED, suggesting that teprotumumab reduces asymmetry.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ugradar S, Wang Y, Mester T, et al. Improvement of asymmetric thyroid eye disease with teprotumumab. Br J Ophthalmol. 2021. PMID: 33579690. doi:10.1136/bjophthalmol-2020-318314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。